Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia
2006 (English)In: Haematologica, ISSN 0390-6078, E-ISSN 1592-8721, Vol. 91, no 9, 1281-2 p.Article in journal (Refereed) Published
Twenty-five patients with myeloproliferative diseases were treated with pegylated interferon alpha-2b. Prior to therapy, 15/25 patients had a JAK2(V617F) mutation. Eight JAK2-positive patients were on therapy in hematological complete remission at 24 months. Five of eight patients demonstrated a 1.2-3.6 fold reduction in the percentage of JAK2(V617F) cells.
Place, publisher, year, edition, pages
2006. Vol. 91, no 9, 1281-2 p.
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-103899PubMedID: 16956836OAI: oai:DiVA.org:uu-103899DiVA: diva2:218959